Valeant relocates Jublia production from Japan to Quebec

Thursday January 21, 2016
Written by Manufacturing AUTOMATION
Jan. 21, 2016 - Valeant Canada has announced its Laval, Que.-based plant will become the North American production site for the prescription medication Jublia, a topical solution that treats toenail fungus. The United States production represents nearly 80 per cent of the total volume of Jublia, which was previously manufactured in Tokyo, Japan, and packaged in the U.S.

So far, this relocation has generated a total investment of more than $1 million for the Laval plant. This investment has helped fund the changes to the medication’s packaging, the construction of specialized rooms used to manipulate ethanol, and improved flammable safety storage units. According to company representatives, the Laval plant now meets global standards and can safely handle a “significant increase” in production volumes.

“Laval is a strategic choice for Valeant. This facility’s lean, state-of-the-art, high-tech manufacturing and efficient production processes have made us competitive on the global stage and helped set our performance apart,” said Jacques Dessureault, president and general manager of Valeant Canada. “As we take on the role of global production centre for prescription dermatology products, this now world-class facility allows us to become a major player in our industry at home and abroad.”

This transfer of production to Laval also guarantees the maintenance of many specialized manufacturing jobs in Quebec, says the company, as well as the “continued sustenance and growth” of Valeant Canada’s operations over the medium term.

Add comment


Security code
Refresh

Subscription Centre

 
New Subscription
 
Already a Subscriber
 
Customer Service
 
View Digital Magazine Renew

We are using cookies to give you the best experience on our website. By continuing to use the site, you agree to the use of cookies. To find out more, read our Privacy Policy.